Breaking News

Pluri Launches Global Cell Therapy CDMO

Will offer manufacturing support from preclinical and development to late stage clinical and commercial production, fill and finish and logistics.

Pluri Inc., a biotech company, launched a new business division offering cell therapy manufacturing services as a contract development and manufacturing organization (CDMO), PluriCDMO. PluriCDMO will offer development and manufacturing services from its state-of-the-art, 47,000 sq.-ft. GMP cell therapy production facility to help customers address key challenges in the development and manufacturing of cell-based therapies. PluriCDMO will offer services for early preclinical development thr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters